Beta vs Alpha RLT in mCRPC — PatSnap Eureka
Beta vs Alpha Radioligand Therapy in mCRPC: PSMA Pipeline Intelligence
¹⁷⁷Lu beta-emitters are commercially approved. ²²⁵Ac alpha-emitters represent the next frontier. Explore the full PSMA-targeted radioligand therapy patent landscape — from Novartis to Fusion Pharmaceuticals — with PatSnap Eureka.
Why PSMA Defines the mCRPC Radioligand Opportunity
Prostate-specific membrane antigen (PSMA), encoded by the gene FOLH1, is a 750-amino acid type II transmembrane glycoprotein with glutamate carboxypeptidase and folate hydrolase activities. Its expression is restricted to prostate epithelium and limited normal tissues — kidney proximal tubules, salivary glands, and small intestinal brush border — but is overexpressed 100- to 1,000-fold in prostate cancer cells relative to normal epithelium, with maximal expression in androgen-independent, metastatic, and high-grade disease: precisely the setting of metastatic castration-resistant prostate cancer (mCRPC).
Multiple retrieved patents from Novartis AG describe methods specifically targeting PSMA-positive progressive mCRPC. PSMA undergoes rapid internalization via clathrin-coated pits and subsequent lysosomal or cell-surface recycling — a mechanism critical to effective radionuclide delivery — as confirmed by Endocyte, Inc. filings. Retrieved data from multiple assignees consistently describe PSMA as carrying up to approximately 10⁶ molecules per cancer cell, enabling high receptor-mediated payload delivery.
Biomarker data from Janssen Pharmaceutica patent intelligence indicate that elevated PSMA expression in circulating tumor cells (CTCs) and tissue correlates with shorter progression-free survival in mCRPC patients receiving androgen receptor pathway inhibitors (ARPIs), supporting PSMA status as both a treatment-selection biomarker and a surrogate for disease aggressiveness. The National Cancer Institute recognizes mCRPC as a leading cause of cancer mortality in men globally.
The secondary molecular context noted across retrieved results includes androgen receptor (AR) pathway status, AR splice variant 7 (ARv7) expression, and co-biomarkers ACADL, NPY, and UBE2C — relevant to treatment sequencing decisions prior to or following RLT.
Beta-Emitters, Alpha-Emitters & Beyond: The PSMA RLT Landscape
Five distinct modality clusters emerge from patent and literature evidence, spanning approved agents through preclinical ligand chemistry innovation.
¹⁷⁷Lu-Labeled Small-Molecule PSMA Ligands
Lutetium-177 (beta emitter, max energy ~0.5 MeV, tissue penetration 1–3 mm) provides a crossfire effect suitable for heterogeneous tumors. The lead compound [¹⁷⁷Lu]Lu-PSMA-617 (lutetium vipivotide tetraxetan) is the most extensively covered agent, with Novartis AG patents spanning WO, US, AU, TW, BR, CN, and KR for taxane-naïve post-ARPI mCRPC. A Fusion Pharmaceuticals 2026 AU filing directly references ¹⁷⁷Lu-PSMA-617 as "recently approved." Point Biopharma's [¹⁷⁷Lu]Lu-PSMA I&T specifies dosing of 6.8 GBq ± 10% per cycle. Cornell University's ¹⁷⁷Lu-RPS-series constructs show up to four-fold higher tumor dose vs PSMA-617 in preclinical models.
Approved (PSMA-617) · Clinical (PSMA I&T)²²⁵Ac-Labeled PSMA Ligands
Actinium-225 (path length ~50–80 µm, linear energy transfer ~80 keV/µm) delivers highly cytotoxic double-strand DNA damage within a very short tissue range, theoretically enabling treatment of micrometastases. Novartis AG's CN patent filing describes PSMA-binding ligand radiolabeled with an alpha-emitting radionuclide at doses of ~6–8 MBq for patients with prior chemotherapy. Endocyte, Inc. filings disclose combination methods using both [¹⁷⁷Lu]-PSMA and [²²⁵Ac]-PSMA conjugates. Fusion Pharmaceuticals (AU 2026) positions ²²⁵Ac as the next-generation agent post-¹⁷⁷Lu approval.
Preclinical → Early Phase INext-Generation PSMA Ligand Scaffolds
Technische Universität München filings describe oligoamide/oligoether linker architectures for PSMA imaging and endoradiotherapy. Johns Hopkins University discloses high-affinity urea-based PSMA inhibitors with ⁹⁹ᵐTc/¹⁸⁶Re/¹⁸⁸Re chelating groups. University of Freiburg CN filings disclose PSMA-binding ligands with neutral amino acid-modified linkers (L^AQ) for improved pharmacokinetics. Cornell University data highlight that short PEG linkers (PEG2–4) are optimal while extended PEG linkers (PEG12, PEG24) reduce PSMA affinity. Tetrakit Technologies ApS describes tetrazine-trans-cyclooctene ligation-based theranostic compounds for in situ radiolabeling.
Preclinical · Theranostic DesignAnti-PSMA Radioimmunotherapy & ADCs
Janssen Biotech, Inc. filings disclose antibodies or antigen-binding fragments against PSMA as radioconjugates and antibody-drug conjugates (ADCs) for cancer treatment. Memorial Sloan Kettering Cancer Center filings describe radiohalogenated (radioiodinated) PSMA theranostic agents for both diagnostic imaging and radiation therapy. These larger-format constructs offer distinct pharmacokinetic profiles compared to small-molecule PSMA ligands, potentially accessing different tumor compartments. Janssen Pharmaceutica NV also contributes extensive biomarker patents characterizing PSMA expression as a predictive and prognostic marker in mCRPC.
Preclinical · RadioimmunotherapyPSMA RLT Pipeline: Data at a Glance
Key metrics from patent and literature analysis of the PSMA-targeted radioligand therapy landscape in mCRPC.
PSMA RLT Modality Pipeline Stages
Beta-emitter programs are furthest advanced; alpha-emitter and novel scaffold programs are in earlier stages based on retrieved patent signals.
Top Assignees by Retrieved Patent Filings
Novartis AG leads with 7+ filings; academic institutions contribute ligand chemistry and safety-enabling IP.
Combination Strategy Patent Signal Distribution
ARPI sequencing and Lu/Ac combination strategies dominate the combination IP landscape in retrieved results.
PSMA Upregulation by Enzalutamide Over Time
PSMA Development Company filings demonstrate enzalutamide upregulates PSMA expression ~2–4 fold over 7–21 days, creating a pharmacological rationale for ARPI → RLT sequencing.
Who Owns the PSMA Radioligand Therapy Patent Space?
Patent activity in this dataset is predominantly commercial for clinical-use methods and academic for ligand chemistry and safety-enabling tools.
| Assignee | Focus Area | Key Jurisdictions | Stage Signal |
|---|---|---|---|
| Novartis AG | ¹⁷⁷Lu-PSMA-617 & ²²⁵Ac treatment methods; taxane-naïve post-ARPI mCRPC | WO, US, AU, TW, BR, CN, KR | Approved |
| Point Biopharma, Inc. | [¹⁷⁷Lu]Lu-PSMA I&T; 6.8 GBq/cycle dosing; AR inhibitor-refractory mCRPC | CA, ID, JP | Clinical |
| Endocyte, Inc. (Novartis) | Foundational ¹⁷⁷Lu + ²²⁵Ac PSMA combination IP; Lu/Ac theranostic space | CA, AU | Clinical |
| Fusion Pharmaceuticals, Inc. | ²²⁵Ac-radioconjugate PSMA pharmaceutical compositions; next-gen alpha-emitter | AU (2026) | Early Clinical |
| Janssen Biotech / Pharmaceutica | Anti-PSMA radioconjugate antibodies; PSMA expression biomarker patents | BR, CN, WO, CA, AU, JP, SG, IL, MX, EP | Early Clinical |
Track New PSMA RLT Filings as They Publish
Set up patent monitoring alerts for any assignee or PSMA RLT technology area in PatSnap Eureka.
Five Strategic Implications for PSMA RLT Drug Developers
Derived from patent and literature evidence across this dataset. Not a comprehensive view of the full clinical or regulatory landscape.
Beta-emitter ¹⁷⁷Lu programs are commercially mature
Novartis AG's multi-jurisdictional method-of-treatment patent estate around [¹⁷⁷Lu]Lu-PSMA-617 represents strong IP entrenchment across taxane-naïve post-ARPI mCRPC. Competitors (Point Biopharma with PSMA I&T; Fusion Pharmaceuticals with ²²⁵Ac-radioconjugates) must differentiate on ligand structure, dosing regimen, or radionuclide class to avoid direct Freedom to Operate conflicts. PatSnap Analytics can map this estate.
Alpha-emitter ²²⁵Ac programs represent the highest-value next frontier
Retrieved filings from Novartis (alpha-targeting RLT regimen, WO 2025), Endocyte (Lu/Ac combination), and Fusion Pharmaceuticals (²²⁵Ac-formula compounds) converge on actinium-225 as the next therapeutic radionuclide. The preclinical-to-early-clinical IP activity suggests a 3–5 year window before alpha-emitter programs reach pivotal stages, representing a significant BD and licensing opportunity.
ARPI-RLT sequencing creates a pharmacologically validated combination rationale
Anti-androgen-induced PSMA upregulation (documented in PSMA Development Company IP) provides a mechanistic basis for combination or sequential ARPI + RLT protocols. Drug developers should consider IP landscapes around sequencing regimens as well as co-formulation strategies. The European Medicines Agency has published guidance on combination oncology trial design relevant here.
Organ-protection cytoprotection is an underappreciated enabling IP space
The Johns Hopkins University's 2-PMPA prodrug family (active in EP) addresses a critical unmet need — salivary and renal toxicity dose-limiting for high-activity PSMA RLT. Licensing or co-development of this technology is strategically important for any developer pursuing higher ²²⁵Ac or escalated ¹⁷⁷Lu dosing. Access the PatSnap customer case studies for licensing deal intelligence examples.
Beyond Monotherapy: The PSMA RLT Combination Pipeline
¹⁷⁷Lu + ²²⁵Ac Sequential/Combination Strategy: Endocyte, Inc. CA and AU patents explicitly disclose methods combining ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA conjugates for PSMA-expressing cancers, with continuation therapy in stable disease. This strategy may address acquired resistance to beta-RLT alone, given the mechanistically distinct DNA-damage profile of alpha emitters. This is the most patent-defined combination in the dataset.
RLT + Second-Generation ARPI Sequencing: Novartis AG patents define a taxane-naïve post-ARPI indication. The PSMA Development Company EP and JP patents demonstrate that anti-androgens (enzalutamide, abiraterone) upregulate PSMA cell surface expression, providing a pharmacological rationale for RLT following ARPI. Retrieved results suggest synergy between PSMA ligand conjugates and anti-androgens on both androgen-dependent and androgen-independent cells. The ClinicalTrials.gov database lists ongoing trials exploring these sequences.
RLT + PARP Inhibitor: The Janux Therapeutics WO and AU filings (2025–2026) describe prior therapy contexts including olaparib, rucaparib, niraparib, talazoparib, or a combination thereof preceding PSMA-targeted RLT in mCRPC, signaling a therapeutic sequence interest in post-PARP-inhibitor RLT use.
Novel Theranostic Scaffolds: Tetrakit Technologies ApS (WO 2025) and Rigshospitalet (EP 2025) tetrazine-trans-cyclooctene ligation-based PSMA compounds represent an emerging direction for in situ radiolabeling efficiency and modular theranostic design. Cornell University RPS-series constructs (CN 2024) show preclinical evidence of significantly higher tumor dosimetry than PSMA-617. Explore the full PatSnap platform for theranostic scaffold landscaping.
The International Atomic Energy Agency (IAEA) has published guidelines on radionuclide therapy dosimetry relevant to combination regimen design and organ-protection strategies.
PSMA Radioligand Therapy in mCRPC — key questions answered
PSMA (prostate-specific membrane antigen; gene FOLH1) is a 750-amino acid, type II transmembrane glycoprotein with glutamate carboxypeptidase and folate hydrolase activities. Its expression is overexpressed 100- to 1,000-fold in prostate cancer cells relative to normal epithelium, with maximal expression in androgen-independent, metastatic, and high-grade disease — precisely the setting of mCRPC. PSMA undergoes rapid internalization via clathrin-coated pits and subsequent lysosomal or cell-surface recycling, a mechanism critical to effective radionuclide delivery.
Lutetium-177 is a beta emitter (maximum energy ~0.5 MeV, tissue penetration 1–3 mm), providing a crossfire effect suitable for heterogeneous tumors with moderate PSMA expression. Alpha-emitting radionuclides — particularly actinium-225 (²²⁵Ac, path length ~50–80 µm, linear energy transfer ~80 keV/µm) — deliver highly cytotoxic double-strand DNA damage within a very short tissue range, theoretically enabling treatment of micrometastases and PSMA-expressing cells not addressable by beta emitters.
Novartis AG is the most active assignee for clinical-use PSMA RLT patents, with at least 7 retrieved filings across WO, US, AU, TW, BR, CN, and KR jurisdictions covering [¹⁷⁷Lu]Lu-PSMA-617 and alpha-emitter treatment regimens in mCRPC. Point Biopharma, Inc. holds patents covering [¹⁷⁷Lu]Lu-PSMA I&T treatment methods. Endocyte, Inc. (now part of Novartis) holds foundational patents for combining ¹⁷⁷Lu and ²²⁵Ac PSMA conjugates. Fusion Pharmaceuticals, Inc. holds a 2026 AU patent filing for ²²⁵Ac-radioconjugate PSMA pharmaceutical compositions.
PSMA Development Company filings demonstrate that enzalutamide treatment upregulates PSMA expression approximately 2–4 fold in prostate cancer cell lines over 7–21 days, providing a mechanistic rationale for combining ARPI therapy with PSMA-targeted RLT. Janssen Pharmaceutica data further show that positive PSMA expression at baseline on CTCs correlates with shorter PFS in chemotherapy-naïve mCRPC patients on abiraterone-prednisone.
The Johns Hopkins University holds a family of patents covering 2-PMPA prodrugs that preferentially distribute to PSMA-expressing normal tissues (kidney, salivary glands, lacrimal glands) to competitively block off-target binding of PSMA-targeted RLT. This represents a safety-enabling modality rather than a therapeutic one, but is mechanistically integral to RLT tolerability.
Retrieved University of Mainz academic literature describes FDG/PSMA-PET mismatch (PSMA-negative, FDG-positive lesions) as a clinically observed resistance mechanism in patients receiving [¹⁷⁷Lu]Lu-PSMA-617, with NSE as an emerging blood biomarker for treatment response stratification. This signals a translational gap that companion diagnostics and combination strategies must address.
Still have questions about PSMA RLT patent intelligence? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka DirectlyAccelerate Your PSMA RLT Drug Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map radioligand therapy patent landscapes, identify BD opportunities, and monitor alpha-emitter pipeline developments.
References
- Uses of PSMA-binding radioligand therapeutic agent (RLT) for the treatment of prostate cancer — Novartis AG, 2025, BR [Patent]
- PSMA-targeting radioligand treatment regimen — Novartis AG, 2025, WO [Patent]
- PSMA-targeting radioligand treatment regimen — Novartis AG, 2026, AU [Patent]
- Method of treating prostate cancer — Novartis AG, 2024, WO [Patent]
- Method of treating prostate cancer — Novartis AG, 2025, AU [Patent]
- Method of treating prostate cancer — Novartis AG, 2024, US [Patent]
- Method of treating prostate cancer — Novartis (Taiwan), 2024, TW [Patent]
- Method of treating prostate cancer — Novartis (Taiwan), 2025, TW [Patent]
- Treatment methods for prostate cancer — Novartis AG, 2025, KR [Patent]
- Radiopharmaceutical treatment methods and use — Point Biopharma, Inc., 2023, CA [Patent]
- Methods of handling radiopharmacy and its use — Point Biopharma, Inc., 2025, ID [Patent]
- Radiopharmaceutical treatment methods and uses — Point Biopharma, Inc., 2024, JP [Patent]
- Methods of treating cancer — Endocyte, Inc., 2020, CA [Patent]
- Methods of treating cancer — Endocyte, Inc., 2021, AU [Patent]
- PSMA-targeted radiopharmaceuticals for treatment of cancer — Fusion Pharmaceuticals Inc., 2026, AU [Patent]
- PSMA ligands for imaging and endoradiotherapy — Technische Universität München, 2022, ES [Patent]
- High-affinity agents targeting prostate-specific membrane antigens for prostate cancer endoradiotherapy — The Johns Hopkins University, 2021, ES [Patent]
- Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy — The Johns Hopkins University, 2025, EP [Patent]
- Radioconjugate Anti-PSMA Agents and Their Use — Janssen Biotech, Inc., 2024, BR [Patent]
- Novel theranostic agents for PSMA positive cancers — Memorial Sloan Kettering Cancer Center, 2022, IL [Patent]
- PSMA theranostic compounds assembled with tetrazine-trans-cyclooctene ligation — Tetrakit Technologies ApS, 2025, WO [Patent]
- National Cancer Institute — Prostate Cancer Research
- European Medicines Agency — Oncology Combination Therapy Guidance
- International Atomic Energy Agency — Radionuclide Therapy Dosimetry Guidelines
- ClinicalTrials.gov — PSMA RLT Combination Trial Registry
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within a limited patent and literature dataset and should not be interpreted as a comprehensive view of the full clinical pipeline, regulatory landscape, or global filing activity.
PatSnap Eureka searches patents and research to answer instantly.